TIAZAC
Details
- Status
- Prescription
- First Approved
- 1995-09-11
- Routes
- ORAL
- Dosage Forms
- CAPSULE, EXTENDED RELEASE
TIAZAC Approval History
What TIAZAC Treats
3 indicationsTIAZAC is approved for 3 conditions since its original approval in 1995. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypertension
- Angina
- Coronary Artery Spasm
Drugs Similar to TIAZAC
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TIAZAC FDA Label Details
ProIndications & Usage
FDA Label (PDF)Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.